VA
FHTX icon

Verdad Advisers’s Foghorn Therapeutics FHTX Stock Holding History

Verdad Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
53,231
+28,815
+118% +$128K 0.25% 129
2026
Q1 		$117K Buy
+24,416
New +$134K 0.13% 151

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Verdad Advisers's FHTX Position: Q2 2026 in Review

Verdad Advisers increased its Foghorn Therapeutics (FHTX) stake by 118% in Q2 2026, buying an estimated $128K and bringing the position to 53,231 shares worth $260K. The position accounts for 0.25% of the portfolio, ranked #129.

Verdad Advisers first reported a position in FHTX in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Verdad Advisers held 53,231 shares of Foghorn Therapeutics worth $260K as of Q2 2026.
  • Verdad Advisers bought 28,815 Foghorn Therapeutics shares in Q2 2026, an estimated $128K.
  • Foghorn Therapeutics made up 0.25% of Verdad Advisers's portfolio in Q2 2026, its #129 holding.
  • Verdad Advisers first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.